MSFT   182.83 (-0.23%)
FB   231.91 (+3.03%)
GOOGL   1,434.87 (+0.09%)
AMZN   2,471.04 (+1.17%)
NVDA   352.25 (-0.78%)
CGC   16.48 (-5.12%)
BABA   206.57 (-0.40%)
MU   46.34 (-3.28%)
TSLA   898.10 (+7.56%)
AMD   53.63 (-0.32%)
T   30.93 (+0.23%)
ACB   14.10 (+0.14%)
F   5.87 (+2.80%)
GILD   75.16 (-3.43%)
DIS   118.77 (+1.25%)
NFLX   425.92 (+1.47%)
BAC   24.61 (+2.03%)
BA   151.39 (+3.80%)
MSFT   182.83 (-0.23%)
FB   231.91 (+3.03%)
GOOGL   1,434.87 (+0.09%)
AMZN   2,471.04 (+1.17%)
NVDA   352.25 (-0.78%)
CGC   16.48 (-5.12%)
BABA   206.57 (-0.40%)
MU   46.34 (-3.28%)
TSLA   898.10 (+7.56%)
AMD   53.63 (-0.32%)
T   30.93 (+0.23%)
ACB   14.10 (+0.14%)
F   5.87 (+2.80%)
GILD   75.16 (-3.43%)
DIS   118.77 (+1.25%)
NFLX   425.92 (+1.47%)
BAC   24.61 (+2.03%)
BA   151.39 (+3.80%)
MSFT   182.83 (-0.23%)
FB   231.91 (+3.03%)
GOOGL   1,434.87 (+0.09%)
AMZN   2,471.04 (+1.17%)
NVDA   352.25 (-0.78%)
CGC   16.48 (-5.12%)
BABA   206.57 (-0.40%)
MU   46.34 (-3.28%)
TSLA   898.10 (+7.56%)
AMD   53.63 (-0.32%)
T   30.93 (+0.23%)
ACB   14.10 (+0.14%)
F   5.87 (+2.80%)
GILD   75.16 (-3.43%)
DIS   118.77 (+1.25%)
NFLX   425.92 (+1.47%)
BAC   24.61 (+2.03%)
BA   151.39 (+3.80%)
MSFT   182.83 (-0.23%)
FB   231.91 (+3.03%)
GOOGL   1,434.87 (+0.09%)
AMZN   2,471.04 (+1.17%)
NVDA   352.25 (-0.78%)
CGC   16.48 (-5.12%)
BABA   206.57 (-0.40%)
MU   46.34 (-3.28%)
TSLA   898.10 (+7.56%)
AMD   53.63 (-0.32%)
T   30.93 (+0.23%)
ACB   14.10 (+0.14%)
F   5.87 (+2.80%)
GILD   75.16 (-3.43%)
DIS   118.77 (+1.25%)
NFLX   425.92 (+1.47%)
BAC   24.61 (+2.03%)
BA   151.39 (+3.80%)
Log in

NASDAQ:RTTRRitter Pharmaceuticals Stock Price, Forecast & News

$0.45
-6.00 (-93.05 %)
(As of 06/1/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.45
Now: $0.45
$0.45
50-Day Range
$0.25
MA: $0.40
$0.72
52-Week Range
$0.15
Now: $0.45
$1.27
VolumeN/A
Average Volume14.23 million shs
Market Capitalization$20.68 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.43
Ritter Pharmaceuticals, Inc. develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.
Read More
Ritter Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.54 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RTTR
CUSIPN/A
Phone310-203-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.10 per share

Profitability

Net Income$-10,130,000.00

Miscellaneous

Employees7
Market Cap$20.68 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive RTTR News and Ratings via Email

Sign-up to receive the latest news and ratings for RTTR and its competitors with MarketBeat's FREE daily newsletter.

Ritter Pharmaceuticals (NASDAQ:RTTR) Frequently Asked Questions

How has Ritter Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Ritter Pharmaceuticals' stock was trading at $0.2680 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, RTTR shares have increased by 67.2% and is now trading at $0.4480. View which stocks have been most impacted by Coronavirus.

When is Ritter Pharmaceuticals' next earnings date?

Ritter Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Ritter Pharmaceuticals.

How were Ritter Pharmaceuticals' earnings last quarter?

Ritter Pharmaceuticals Inc (NASDAQ:RTTR) posted its quarterly earnings data on Friday, May, 1st. The biotechnology company reported ($0.05) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.04) by $0.01. View Ritter Pharmaceuticals' earnings history.

When did Ritter Pharmaceuticals' stock split? How did Ritter Pharmaceuticals' stock split work?

Ritter Pharmaceuticals's stock reverse split on the morning of Friday, March 23rd 2018. The 1-10 reverse split was announced on Thursday, March 22nd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 22nd 2018. An investor that had 100 shares of Ritter Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

Has Ritter Pharmaceuticals been receiving favorable news coverage?

News headlines about RTTR stock have been trending extremely negative this week, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ritter Pharmaceuticals earned a news sentiment score of -5.0 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news aboutRitter Pharmaceuticals.

Who are some of Ritter Pharmaceuticals' key competitors?

What other stocks do shareholders of Ritter Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ritter Pharmaceuticals investors own include Endologix (ELGX), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Apache (APA), Charles Schwab (SCHW), Genocea Biosciences (GNCA), Hudson Technologies (HDSN), Vicor (VICR), Zoetis (ZTS) and Primo Water (PRMW).

Who are Ritter Pharmaceuticals' key executives?

Ritter Pharmaceuticals' management team includes the following people:
  • Mr. Ira Eliot Ritter, Co-Founder, Exec. Chairman & Chief Strategic Officer (Age 70)
  • Mr. Andrew J. Ritter, Co-Founder, CEO, Pres, Corp. Sec. & Director (Age 36)
  • Mr. Michael D. Step, Consultant & Director (Age 59)
  • Mr. John W. Beck CPA, CPA, Chief Financial Officer (Age 59)
  • Ms. Ellen F. Mochizuki, Consultant (Age 52)

When did Ritter Pharmaceuticals IPO?

(RTTR) raised $20 million in an IPO on Wednesday, June 24th 2015. The company issued 4,000,000 shares at a price of $5.00 per share. Aegis Capital Corp and Chardan Capital Markets served as the underwriters for the IPO and Barrington Research was co-manager.

What is Ritter Pharmaceuticals' stock symbol?

Ritter Pharmaceuticals trades on the NASDAQ under the ticker symbol "RTTR."

How do I buy shares of Ritter Pharmaceuticals?

Shares of RTTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ritter Pharmaceuticals' stock price today?

One share of RTTR stock can currently be purchased for approximately $0.45.

How big of a company is Ritter Pharmaceuticals?

Ritter Pharmaceuticals has a market capitalization of $20.68 million. Ritter Pharmaceuticals employs 7 workers across the globe.

What is Ritter Pharmaceuticals' official website?

The official website for Ritter Pharmaceuticals is www.ritterpharmaceuticals.com.

How can I contact Ritter Pharmaceuticals?

Ritter Pharmaceuticals' mailing address is 1880 CENTURY PARK EAST SUITE 1000, LOS ANGELES CA, 90067. The biotechnology company can be reached via phone at 310-203-1000 or via email at j[email protected]

This page was last updated on 6/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.